Navigation Links
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
Date:4/19/2009

-- Data presented at 100th Annual Meeting of the American Association for Cancer Research --

SEATTLE and DENVER, April 19 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) presented today data from its PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE(R) (sipuleucel-T) induces long-term memory immune responses that are durable and can be maintained following boosting. The results of the study also indicate that CD54 upregulation on Antigen Presenting Cells (APCs), a measure of potency, is a correlate of immune activation.

P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate. Patients were randomized to PROVENGE or placebo following 3 months of hormone therapy. This study evaluated CD54 upregulation and peripheral immune responses in men enrolled in the trial.

PROVENGE or placebo was administered at weeks zero, two and four. A treatment booster infusion of PROVENGE or placebo was offered after confirmed PSA greater than or equal to 3.0ng/mL. Immune responses were measured pre-treatment, at weeks four and 13, and at four and 13 weeks following the booster infusion.

At the week zero dose of PROVENGE, the expression of CD54 on APCs was upregulated 5.8 fold. At the week two dose, it was 10.1 fold, significantly increased from week 0 (p < 0.001). The increase in CD54 upregulation persisted at week four (10.7 fold) and at the time of the booster infusion (12.0 fold). There was an increase in cellular immune response between pre-treatment and week four (p < 0.001), which persist
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
2. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
3. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
4. Dendreon Reports Third Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
10. Dendreon Reports First Quarter 2008 Financial Results
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical device ... to participate in the 19th Annual Piper Jaffray,Health Care ... on Tuesday,November 27, 2007. Steven G. Anderson, president ... beginning at approximately 1:30 p.m. EST. CryoLife,s live ...
... pm ET on November 27, 2007, CAMBRIDGE, Mass., ... today announced its participation,in the Lazard Capital Markets Fourth ... at the New York Palace Hotel in New York,City. ... be presenting at 2:00 pm ET on Tuesday, November ...
... Scientists have announced,that they successfully reprogrammed adult ... of patient-specific medical treatments and,research without the need ... the Discovery Institute,s Senior Fellow in Bioethics,and author ... hailed the,breakthrough as demonstrating that ethical science is ...
Cached Biology Technology:CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York 2Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference 2
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... from the north-central U.S. and beyond will convene in Kalamazoo, ... and discuss new science, expand on existing science, and explore ... a special emphasis on the Great Lakes. Events include a ... by William F. Ruddiman titled, "When Did We Transform Earth,s ...
... York, NY (April 18, 2013) An excess of ... psychosis in people who are at risk for schizophrenia, ... Center (CUMC) published in the current issue of ... diagnostic tool for identifying those at risk for schizophrenia ...
... IOF Medal of Achievement has been presented today to ... Department of Internal Medicine, Hospital del Mar, Director of ... Institute of Medical Research and Professor of Medicine at ... Foundation (IOF) awards the IOF Medal of Achievement every ...
Cached Biology News:Kalamazoo center of geologic focus this May 2High levels of glutamate in brain may kick-start schizophrenia 2IOF Medal of Achievement awarded to Professor Adolfo Diez-Perez 2
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
... Novagens PhageMaker System is optimized for maximum ... ligated with any bacteriophage l vector. Using a ... > 10^7 pfu/g arms (> 4 x 10^8 ... This one-tube system is extremely easy to use; ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Polymerase (RNA) II (DNA directed) polypeptide L...
Biology Products: